Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cash and texts keep psychosis patients in care?

NCT ID NCT05967195

Ongoing Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether offering small financial rewards (up to $50/month) and text reminders can encourage people with first-episode psychosis to attend their therapy and medication appointments. About 145 participants from two specialty clinics will take part over three 3-month periods, with adjustments made based on feedback. The goal is to see if this simple approach is acceptable and feasible for patients and clinicians.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
financial incentives and text messages
What this could lead to
If successful, this approach could improve treatment attendance and outcomes for people with early psychosis, reducing risks like suicide.
What could go wrong
This is a very early pilot study with only 145 participants, so results may not apply broadly. The intervention is modest and may not significantly change behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST-EPISODE PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST-EPISODE PSYCHOSIS

Contacts and locations

Locations

  • PEACE Program, Horizon House, Inc.

    Philadelphia, Pennsylvania, 19123, United States

  • University of North Carolina at Chapel Hill (ENCOMPASS Program)

    Raleigh, North Carolina, 27608, United States

  • University of Pennsylvania

    Philadephia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.